ELICIO THERAPEUTICS INC. reports a Return on Equity (ROE) of 2,796.45%.

What is ELTX's dividend yield?

ELICIO THERAPEUTICS INC. offers a dividend yield of 0.00%.

What is ELTX's Quality Score?

Our AI rates ELTX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ELTX?

Our AI Timing Score for ELTX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ELTX belong to?

ELICIO THERAPEUTICS INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

ELTX (NASDAQ) Stock Analysis | ELICIO THERAPEUTICS INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ELTX AI Analysis Summary

Our AI summary for ELTX: ELICIO THERAPEUTICS INC. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 2,796.45%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ELTX

ELICIO THERAPEUTICS INC.

US:NASDAQ STOCK Healthcare >> Biotechnology News 63

USD 2.80

-0.11 (-3.78%) Day Change

Watchlist Portfolio Compare Chart

-7.32

D/E

2,796.5%

ROE

-177.1%

ROA

0.00%

Div Yield

ELICIO THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.80 Price -0.11 (-3.78%) Day Change	NEWS SCORE: 63

ELTX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	63
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.80
PBV / Sector	-53.19 / 5.20
Earning Per Share	-1.47

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	2.36 M GREAT
Average 1W Daily Value	0.85 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-177.11 / 27.02
ROA Average (%) / Sector	-153.68 / -368.17
ROA Change Average (%) / Sector	11.26 / 5,404.12 GOOD
ROE (%) / Sector	2,796.45 / 3.47
ROE Average (%) / Sector	42.12 / 6.51 GREAT
ROE Change Average (%) / Sector	-273.32 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:46
Symbol	ELTX
Name	ELICIO THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	26.26 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	76.43 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 451 D Street, Boston, MA, United States, 02210

Phone: 857 209 0050

Website: https://elicio.com

Sector: Healthcare >> Biotechnology

Description: Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.